The Regulatory Role of Lipid Metabolism in Endometrial Cancer

Abstract

Endometrial cancer is the 6th most common carcinoma as well as the 2nd most common malignancy worldwide in women. It is closely related to fat content, and dyslipidemia is among the most significant metabolic changes in this cancer. Therefore, further understanding of the regulation mechanism in lipid metabolism of endometrial cancer is conducive to the development of better therapeutic strategies and methods. Here, we systematically review the signaling pathways that regulate lipid metabolism in endometrial cancer and the research progress of drugs and targeted therapies that act on lipid metabolism by retrieving relevant articles. The underlying mechanism of occurrence and development of endometrial cancer is relatively clear and comprehensively reviewed here. But following more research studies will help to illuminate more specific regulatory roles of lipid metabolism in endometrial cancer and explore new possible mechanisms, prognostic and therapeutic targets, and subsequent drugs. Our review will provide a full view for the following investigation of lipid metabolism in endometrial cancer.

ERRα Up-Regulates Invadopodia Formation by Targeting HMGCS1 to Promote Endometrial Cancer Invasion and Metastasis

“…Dyslipidemia is one of the most significant metabolic changes in EC. A greater understanding of the regulatory mechanism of lipid metabolism in EC will facilitate the development of improved therapeutic strategies for EC [ 33 ]. We found a biomarker of EC progression based on lipid metabolism, which explains the clinical phenomenon that patients with EC often have abnormal lipid metabolism.…”

Metabolic Syndrome and Survival Outcomes in Endometrial Cancer

“…Studies show a significantly higher prevalence of metabolic disorders following surgical menopause compared to natural menopause. This association is linked to the sudden decline in estrogen levels caused by surgery, which can lead to endothelial dysfunction, dyslipidemia [1,[26][27][28][29], and increased risk of cardiovascular events [30][31][32][33][34]. Research suggests a 1.5-fold to 9.7-fold increased risk of MetS in women who undergo surgical menopause compared to natural menopause [1,[35][36][37][38][39].…”

LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior

“…When diagnosed in the early stages, the tumour is confined to the uterus and can be treated with total hysterectomy and bilateral salpingo-oophorectomy, with a five-year survival rate ranging from 74% to 91% [3]. If the diagnosis was delayed and the tumour progresses to local or distant metastases, chemotherapy would then have to be administered but the five-year survival rate would drop dramatically [4]. Frustratingly, screening AGING tests for UCEC are not yet in place, the available biomarkers are not yet used for routine diagnosis and prognostic assessment, and confirmation of diagnosis still hinges on pathological endometrial biopsy [5,6].…”